Login
$WST
$417.41 +$0.99 (0.24%) Live

$WST SEC Filings

Filed On Filing
05 Nov 2026 SCHEDULE 13G/A
29 Oct 2026 10-Q
29 Oct 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Raising Full-Year Net Sales and Adjusted-Diluted EPS guidance

26 Oct 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more

EXECUTION VERSION Credit Agreement - West Pharma (2026) (Conformed Signatures for 8-K Filing)(24019362844.2) - 10/26/2026 3:26:03 PM Deal CUSIP Number: 95530RAH2 Revolver A: 95530RAJ8 Revolver B: 95530RAL3 Term A Facility: 95530RAK5 CRED...

02 Oct 2026 Form 4: Haugen Janet Brutschea, Director

Granted 44 Phantom Stock Unit ($16.3K)

15 Sep 2026 Form 4: Favorite Annette F, Sr. VP & Chief HR Officer

Received 2,500 shares by exercise or conversion ($224K) · Sold 2,500 shares ($863K) · Received 2,500 shares by exercise or conversion ($224K) · 3 more

10 Sep 2026 Form 4: Favorite Annette F, Sr. VP & Chief HR Officer

Received 8,135 shares by exercise or conversion ($694K) · Sold 8,135 shares ($2.77M)

10 Sep 2026 Form 4: Lagarde Michel, Director

Granted 37,048 Stock Option (Right to Buy) · Granted 14,750 Rst. Stock Unit

10 Sep 2026 Form 3: Lagarde Michel, Director

Holds 7,850 shares of Common Stock

12 Aug 2026 Form 4: McMahon Robert W., SVP & Chief Financial Officer

Received 7,149.205 shares by exercise or conversion · Gave up 3,109.19 shares to cover exercise price or tax ($1.09M)

06 Aug 2026 SCHEDULE 13G
23 Jul 2026 10-Q
23 Jul 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Exton, PA, July 23, 2026 – West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the second quarter of 2026.

14 Jul 2026 8-K: Entry into a Material Definitive Agreement

West Pharmaceutical Services, Inc. (the "Company") and Daikyo Seiko, Ltd. ("Daikyo") have entered into an Amended and Restated Technology Exchange and Crosslicense Agreement (the “Crosslicense Agreement”) as well as two Distributorship A...

01 Jul 2026 Form 4: Haugen Janet Brutschea, Director

Granted 46 Phantom Stock Unit ($16.5K)

01 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) dated as of May 31, 2026 (the “Effective Date”) is entered by and between West Pharmaceutical Services, Inc., a Pennsylvania corporation (the “Company...

20 May 2026 8-K/A: Material Cybersecurity Incidents

As previously disclosed in the Original Report, the Company determined on May 7, 2026 that the Company had experienced a material cybersecurity attack, in which certain data was exfiltrated by an unauthorized party and certain systems we...

14 May 2026 Form 4: Campbell Shane Alden, SVP, Proprietary Segment

Received 769.588 shares by exercise or conversion · Gave up 219.256 shares to cover exercise price or tax ($68.4K)

13 May 2026 SD
11 May 2026 8-K: Material Cybersecurity Incidents; Regulation FD Disclosure

West is committed to providing timely and transparent communication to all stakeholders regarding the recent cyberattack on its network systems. Following initial detection of an intrusion on May 4, 2026, West Pharmaceutical Services pro...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support